- Home
- IDR vs SERA Comparison
IDR vs SERA Comparison
Compare IDR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- SERA
- Stock Information
- Founded
- IDR 1996
- SERA 2008
- Country
- IDR United States
- SERA United States
- Employees
- IDR N/A
- SERA N/A
- Industry
- IDR Precious Metals
- SERA Precision Instruments
- Sector
- IDR Basic Materials
- SERA Health Care
- Exchange
- IDR Nasdaq
- SERA Nasdaq
- Market Cap
- IDR 154.1M
- SERA 142.9M
- IPO Year
- IDR N/A
- SERA 2021
- Fundamental
- Price
- IDR $14.31
- SERA $3.68
- Analyst Decision
- IDR Strong Buy
- SERA
- Analyst Count
- IDR 1
- SERA 0
- Target Price
- IDR $14.00
- SERA N/A
- AVG Volume (30 Days)
- IDR 165.5K
- SERA 105.6K
- Earning Date
- IDR 05-05-2025
- SERA 03-19-2025
- Dividend Yield
- IDR N/A
- SERA N/A
- EPS Growth
- IDR 344.26
- SERA N/A
- EPS
- IDR 0.67
- SERA N/A
- Revenue
- IDR $25,765,373.00
- SERA $77,000.00
- Revenue This Year
- IDR $86.37
- SERA $4,536.36
- Revenue Next Year
- IDR $11.11
- SERA $411.43
- P/E Ratio
- IDR $21.37
- SERA N/A
- Revenue Growth
- IDR 64.94
- SERA N/A
- 52 Week Low
- IDR $7.59
- SERA $3.33
- 52 Week High
- IDR $18.35
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- IDR 62.44
- SERA 37.12
- Support Level
- IDR $13.20
- SERA $3.77
- Resistance Level
- IDR $14.22
- SERA $4.20
- Average True Range (ATR)
- IDR 0.79
- SERA 0.24
- MACD
- IDR 0.18
- SERA 0.01
- Stochastic Oscillator
- IDR 97.19
- SERA 34.83
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.